Evidence map›Paper›PMID 41102523›Full record

ArticleScientific reports2025

CRISPR screen reveals SOX2 as a critical regulator of CD133 and cellular stress response in glioblastoma.

Neil Savage, Etienne Danis, Chirayu R Chokshi, Stefan Custers, Muhammad Vaseem Shaikh, Petar Miletic, Chitra Venugopal, Kevin R Brown, Rajeev Vibhakar, Jason Moffat and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. The Role of CRISPR and Its Therapeutic Applications in Glioblastoma.International journal of molecular sciences · 2026
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Neil SavageDepartment of Biochemistry and Biomedical Sciences, McMaster University, Hamilton, ON, L8N 3Z5, Canada.
Etienne DanisUniversity of Colorado Cancer Center, University of Colorado Anschutz Medical Campus, Aurora, CO, USA.
Chirayu R ChokshiDepartment of Biochemistry and Biomedical Sciences, McMaster University, Hamilton, ON, L8N 3Z5, Canada.
Stefan CustersDepartment of Biochemistry and Biomedical Sciences, McMaster University, Hamilton, ON, L8N 3Z5, Canada.
Muhammad Vaseem ShaikhCentre for Discovery in Cancer Research (CDCR), McMaster University, Hamilton, ON, L8S 3Z5, Canada.
Petar MileticCentre for Discovery in Cancer Research (CDCR), McMaster University, Hamilton, ON, L8S 3Z5, Canada.
Chitra VenugopalCentre for Discovery in Cancer Research (CDCR), McMaster University, Hamilton, ON, L8S 3Z5, Canada.
Kevin R BrownDonnelly Centre, University of Toronto, Toronto, ON, M5S 3E1, Canada.
Rajeev VibhakarUniversity of Colorado Cancer Center, University of Colorado Anschutz Medical Campus, Aurora, CO, USA.
Jason MoffatDonnelly Centre, University of Toronto, Toronto, ON, M5S 3E1, Canada.
Sheila K SinghDepartment of Biochemistry and Biomedical Sciences, McMaster University, Hamilton, ON, L8N 3Z5, Canada. ssingh@mcmaster.ca.

Funding

Terry Fox Research Institute Program Project Grant 1065
6 · The paper itself

Abstract

Glioblastoma (GBM) remains a formidable challenge in clinical settings due to limited treatments available. The surface protein CD133 marks glioblastoma stem cells (GSCs), cells capable of overcoming therapeutic pressures and correlate with more aggressiveness tumor phenotypes. In this study, we employed a CRISPR-Cas9 functional screen to deconvolute CD133 dynamics in tumors. This led us to establish that SOX2 is a key player in controlling the PROM1 gene, which in turn influences how cells react to stress factors, including those induced by chemoradiation treatment. The discoveries in this study shed light on the complex web of mechanisms that control the survival and resistance of GSCs, offering promising new avenues for targeting and potentially overcoming therapy resistance.

Indexed as

AC133 AntigenBrain NeoplasmsCRISPR-Cas SystemsGlioblastomaSOXB1 Transcription FactorsStress, PhysiologicalAnimalsCell Line, TumorGene Expression Regulation, NeoplasticHumansMiceNeoplastic Stem CellsAC133 AntigenPROM1 protein, humanSOX2 protein, humanSOXB1 Transcription Factors

Identifiers

PMID41102523
PMCPMC12533111

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.